Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T
21/07/2026 12:24
BRIEF-Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T July 21 (Reuters) - Tempest Therapeutics Inc TPST.O:
TEMPEST ANNOUNCES DEVELOPMENT COLLABORATION WITH SENLANG BIOTECHNOLOGY FOR TPST-4003, A CD7-TARGETED NEXT-GENERATION IN VIVO CAR-T
TEMPEST THERAPEUTICS - FIRST PATIENT DOSING FOR TPST-4003 TRIAL EXPECTED IN Q4 2026
TEMPEST THERAPEUTICS - CO AND SENLANG TO DEVELOP TPST-4003 WITH TRIAL IN CHINA FOR MG AND MS
Source text: ID:nGNX9T07mm
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T